Connective Portfolio Management LLC purchased a new position in shares of Galapagos NV (NASDAQ:GLPG – Get Rating) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $643,000.
Other large investors also recently bought and sold shares of the company. Signaturefd LLC grew its stake in shares of Galapagos by 109.5% during the 4th quarter. Signaturefd LLC now owns 505 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 264 shares during the period. Advisor Group Holdings Inc. grew its stake in shares of Galapagos by 61.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,226 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 467 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Galapagos during the 3rd quarter worth $794,000. Cinctive Capital Management LP acquired a new position in shares of Galapagos during the 4th quarter worth $1,549,000. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Galapagos during the 4th quarter worth $1,709,000. 18.25% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on GLPG. Morgan Stanley upped their price target on shares of Galapagos from $77.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, February 28th. JPMorgan Chase & Co. increased their price objective on shares of Galapagos from €60.00 ($63.16) to €65.00 ($68.42) and gave the company a “neutral” rating in a research note on Thursday, May 12th. UBS Group increased their price objective on shares of Galapagos from €52.00 ($54.74) to €70.00 ($73.68) and gave the company a “neutral” rating in a research note on Thursday, May 12th. Finally, StockNews.com initiated coverage on shares of Galapagos in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.97.
Galapagos (NASDAQ:GLPG – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.68. Galapagos had a negative net margin of 25.71% and a negative return on equity of 4.77%. The company had revenue of $152.99 million for the quarter, compared to analysts’ expectations of $97.16 million. On average, research analysts anticipate that Galapagos NV will post -2.38 EPS for the current fiscal year.
Galapagos Company Profile (Get Rating)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
- The Rebound In Winnabego Is On
- Global Events Could Be A Boon For Potash Stocks
- SeaWorld Entertainment Stock Can be Caught on the Downdraft
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.